Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in alzheimer's disease patients

Journal of Alzheimer's Disease

Volumn 40, Issue 3, 2014, Pages 737-742

  Bracco, Laura ^a   Bessi, Valentina ^a   Padiglioni, Sonia ^a   Marini, Sandro ^a   Pepeu, Giancarlo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acetylcholine; attention; cholinergic system; donepezil; galantamine; rivastigmine

Indexed keywords

ACETYLCHOLINE; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; HAMILTON SCALE; HUMAN; LONG TERM MEMORY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITION DISORDERS; COMPLICATION; COMPUTED TOMOGRAPHY SCANNER; MENTAL HEALTH; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 84901953748     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131154     Document Type: Article

References (52)

1. DSM-IV Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC.
2. Perry RJ, Hodges JR (1999) Attention and executive deficits in Alzheimer's disease. A critical review. Brain 122(Pt 3), 383-404. (Pubitemid 29110515)
3. Kolanowski AM, Fick DM, Yevchak AM, Hill NL, Mulhall PM, McDowell JA (2012) Pay attention! The critical importance of assessing attention in older adults with dementia. J Gerontol Nurs 38, 23-27.
4. Brown SC, Craik FIM (2000) Encoding and retrieval of information. In The Oxford Handbook of Memory,Tulving E, Craik FIM, eds. Oxford University Press, Oxford, pp. 93-107.
5. Miloyan BH, Razani J, Larco A, Avila J, Chung J (2013) Aspects of attention predict real-world task performance in Alzheimer's disease. Appl Neuropsychol Adult 20, 203-210.
6. Baddeley AD, Baddeley HA, Bucks RS,Wilcock GK (2001) Attentional control in Alzheimer's disease. Brain 124, 1492- 1508. (Pubitemid 32726764)
7. Daiello LA, Ott BR, Festa EK, Friedman M, Miller LA, Heindel WC (2010) Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease. J Clin Psychopharmacol 30, 245-251.
8. Belleville S, ChertkowH, Gauthier S (2007)Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment. Neuropsychology 21, 458- 469. (Pubitemid 47445217)
9. Everitt BJ, Robbins TW (1997) Central cholinergic systems and cognition. Annu Rev Psychol 48, 649-684. (Pubitemid 127485189)
10. Demeter E, Sarter M (2013) Leveraging the cortical cholinergic system to enhance attention. Neuropharmacology 64, 294-304.
11. Sarter M, Gehring WJ, Kozak R (2006) More attention must be paid: The neurobiology of attentional effort. Brain Res Rev 51, 145-160. (Pubitemid 43902969)
12. Sarter M, Paolone G (2011) Deficits in attentional control: Cholinergic mechanisms and circuitry-based treatment approaches. Behav Neurosci 125, 825-835.
13. Klinkenberg I, Sambeth A, Blokland A (2011) Acetylcholine and attention. Behav Brain Res 221, 430-442.
14. Pepeu G, Giovannini MG (2006) The role of the cholinergic system in cognitive processes. In The Brain Cholinergic System, Giacobini E, Pepeu G, eds. Informa Healthcare, Abingdon UK, pp. 221-233
15. FureyML, Pietrini P, Haxby JV, DrevetsWC(2008) Selective effects of cholinergic modulation on task performance during selective attention. Neuropsychopharmacology 33, 913-923. (Pubitemid 351252696)
16. FureyML, Pietrini P, Haxby JV (2000) Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 290, 2315.
17. Thienel R, Kellermann T, Schall U, Voss B, ReskeM, Halfter S, Sheldrick AJ, Radenbach K, Habel U, Shah NJ, Kircher T (2009) Muscarinic antagonist effects on executive control of attention. Int J Neuropsychopharmacol 12, 1307-1317.
18. Thienel R, Voss B, Kellermann T, Reske M, Halfter S, Sheldrick AJ, Radenbach K, Habel U, Shah NJ, Schall U, Kircher T (2009) Nicotinic antagonist effects on functional attention networks. Int J Neuropsychopharmacol 12, 1295- 1305.
19. Mesulam M-M, Mufson EJ, Wainer BH, Levey AI (1983) Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10, 1185-1201. (Pubitemid 14178569)
20. Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-417. (Pubitemid 12048290)
21. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP,Wieland DM, Koeppe RA (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40, 399-410. (Pubitemid 26304797)
22. Rodda J, Walker Z (2009) Ten years of cholinesterase inhibitors. Int J Geriatr Psychiatry 24, 437-442.
23. Pepeu G, Giovannini MG (2009) Cholinesterase inhibitors and beyond. Curr Alzheimer Res 6, 86-96.
24. Kikuchi T, Okamura T, Fukushi K, Takahashi K, Toyohara J, Okada M, Zhang MR, Irie T (2007) Cerebral acetylcholinesterase imaging: Development of the radioprobes. Curr Top Med Chem 7, 1790-1799.
25. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ,Koeppe RA, Meltzer CC, Constantine G,Davis JG, Mathis CA, DeKosky ST, Moore RY (2005) Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 76, 315-319. (Pubitemid 40299116)
26. Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A (2006) PET imaging of cortical C-11-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology 188, 509-520. (Pubitemid 46758966)
27. McKhann, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
28. Bracco L, Amaducci L, Pedone D, Bino G, Lazzaro MP, Carella F, Dantona R, Gallato R, Denes G (1990) Italian Multicentre Study on Dementia (SMID): A neuropsychological test battery for assessing Alzheimer's disease. J Psychiatr Res 24, 213-226. (Pubitemid 20347106)
29. Brooks JO, Jesavage JA, Taylor J, Friedman L, Tanke ED, LubyV, Tinklenber J (1993) Cognitive decline in Alzheimer's disease: Elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination. Int Psychogeriatry 5, 135-146. (Pubitemid 23362838)
30. Salmon DP, Thal LJ, Butters N, Heindel WC (1990) Longitudinal evaluation of dementia of the Alzheimer type - a comparison of 3 standardized mental status examinations. Neurology 40, 1225-1230. (Pubitemid 20244980)
31. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA (2000) Modelling Mini Mental State Examination changes in Alzheimer's disease. Stat Med 19, 1607-1616. (Pubitemid 30346250)
32. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, Gonzales N, Lai E, Massman P (2001) Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12, 295- 300. (Pubitemid 32429729)
33. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57, 489-495. (Pubitemid 32757598)
34. Yaguez L, Shaw KN, Morris R, Matthews D (2011) The effects on cognitive functions of a movement-based intervention in patients with Alzheimer's type dementia:Apilot study. Int J Geriatr Psychiatry 26, 173-181.
35. Viola LF, Nunes PV, Yassuda MS, Aprahamian I, Santos FS, Santos GD, Brum PS, Borges SM, Oliveira AM, Chaves GF, Ciasca EC, Ferreira RC, Paula VJ, Takeda OH, Mirandez RM, Watari R, FalcaoDV, Cachioni M, ForlenzaOV(2011) Effects of a multidisciplinary cognitive rehabilitation program for patients with mild Alzheimer's disease. Clinics (Sao Paulo) 66, 1395-1400.
36. MohsRC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57, 481-488. (Pubitemid 32757597)
37. Rountree SD, Chan WY, Pavlik VN, Darby EJ, Siddiqui S, Doody RS (2009) Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 1, 7.
38. Gauthier S, Juby A, Dalziel W, Rehel B, Schecter R (2010) Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). Curr Med Res Opin 26, 1149-1160.
39. Machado TH, Charcat Finchman H, Santos EL, Carvalho VA, Paes Fialho P, Koenig AM, Santos Fernandez C, Lourenco RA, Martins de Paiva Paradela E, Caramelli P (2009) Normative data for healthy elderly on the phonemic verbal fluency task - FAS. Dement Neuropsychol 3, 55-60.
40. Tombaugh TN (2004) Trail Making Test A and B: Normative data stratified by age and education. Arch Clin Neuropsychol 19, 203-214. (Pubitemid 38316871)
41. Laatu S, Revonsuo A, Jaykka H, Portin R, Rinne JO (2003) Visual object recognition in early Alzheimer's disease: Deficits in semantic processing. Acta Neurol Scand 108, 82-89. (Pubitemid 36920655)
42. Galvin JE, Cornblatt B, Newhouse P, Ancoli-Israel S,Wesnes K,Williamson D, Zhu Y, Sorra K, Amatniek J (2008) Effects of galantamine on measures of attention: Results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Dis Assoc Disord 22, 30-38. (Pubitemid 351651395)
43. Kasuya M, Meguro K, Okamura N, Funaki Y, Ishikawa H, Tanaka N, Iwata R, Yanai K (2012) Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study. Alzheimer Dis Assoc Disord 26, 113-118.
44. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R (1993) Further analysis of the cognitive effects of tetrahydroaminoacridine (Tha) in Alzheimer's disease - assessment of attentional and mnemonic function using Cantab. Psychopharmacology 110, 395-401. (Pubitemid 23074561)
45. Bentley P, Driver J, Dolan RJ (2008) Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health. Brain 131, 409-424. (Pubitemid 351197610)
46. Foldi NS, White REC, Schaefer LA (2005) Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. Int J Geriatr Psychiatry 20, 485-488. (Pubitemid 40716343)
47. Miettinen PS, Pihlajamaki M, Jauhiainen AM, Tarkka IM, Grohn H, Niskanen E, Hanninen T, Vanninen R, Soininen H (2011) Effect of cholinergic stimulation in early Alzheimer's disease - functional imaging during a recognition memory task. Curr Alzheimer Res 8, 753-764.
48. Brousseau G, Rourke BP, Burke B (2007) Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: An alternate hypothesis to global cognitive enhancement. Exp Clin Psychopharmacol 15, 546-554. (Pubitemid 351163129)
49. Dumas JA, Newhouse PA (2011) The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation. Pharmacol Biochem Behav 99, 254-261.
50. Dunne MP, Hartley LR (1986) Scopolamine and the control of attention in humans. Psychopharmacology 89, 94-97. (Pubitemid 16062970)
51. Van Hoesen GW, Hyman BT, Damasio AR (1986) Cellspecific pathology in neural systems of the temporal lobe in Alzheimer's disease. Prog Brain Res 70, 321-335.
52. Mumenthaler MS, Yesavage JA, Taylor JL, O'Hara R, Friedman L, Lee H, Kraemer HC (2003) Psychoactive drugs and pilot performance: A comparison of nicotine, donepezil, and alcohol effects. Neuropsychopharmacology 28, 1366-1373. (Pubitemid 41070908)